Al-Wakeel Yasir B. 4

What Happened

• Yasir B. Al‑Wakeel, a director of Maxcyte, Inc. (MXCT), received two awards on June 17, 2026 totaling 80,000 restricted stock units (RSUs): 30,421 RSUs and 49,579 RSUs. Both were granted at $0.00 per share (no cash paid); the reported acquisition value is $0. These are awards (transaction code A) rather than purchases or sales.

Key Details

• Transaction date: June 17, 2026; Filing date: June 22, 2026 (filed late relative to the trade date).
• Grant specifics: 30,421 RSUs (footnote: each RSU is a contingent right to one share); 49,579 RSUs (noted as the annual non‑employee director grant).
• Vesting: The 49,579 RSUs are an annual director grant that vests on June 17, 2027, subject to the reporting person's continuous service. The filing does not specify a vesting schedule for the 30,421 RSUs beyond their characterization as RSUs.
• Shares owned after transaction: Not disclosed in this Form 4 filing.
• Transaction type: Awards/Grants (derivative RSUs), not open‑market buys or sales.

Context

• RSUs are contingent rights that convert into common shares upon vesting; they are derivative awards, not immediate share transfers. Because these are grants to a non‑employee director under the company’s Equity Grant Policy, they are generally routine compensation and do not by themselves indicate buying or selling sentiment. The filing was submitted five days after the transaction date, which is later than the normal two‑business‑day Form 4 filing window.